Mexico’s Cofepris has granted marketing authorization for lenacapavir as twice-yearly injectable pre-exposure prophylaxis against HIV, placing Mexico among a small group of countries with regulatory access to the long-acting prevention …
Mexico’s Cofepris has granted marketing authorization for lenacapavir as twice-yearly injectable pre-exposure prophylaxis against HIV, placing Mexico among a small group of countries with regulatory access to the long-acting prevention …
Donanemab is now infused in a Mexican public hospital. Lilly’s 2026 target: 30 patients — the gap between innovation and the system, in one number.
Mexico’s Cofepris has established an abbreviated registration pathway recognising ANVISA evaluations, with a 45-business-day resolution ceiling — accelerating market entry for manufacturers already cleared in Brazil.
You must be logged in to post a comment.